Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
AssigneesTransgene S.A., Merck Patent GmbH, Pfizer Inc.
InventorsKaidre BENDJAMA, Maud BRANDELY-TALBOT, Annette TAVERNARO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of a) a poxvirus vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and an immunostimulatory cytokine, and b) an anti-PD-L1 antibody or antigen-binding fragment thereof, for use in the treatment of an HPV-positive cancer, wherein a first administration of said poxvirus is performed 5 to 10 days before the first administration of said anti-PD-L1 antibody, and subsequent administrations of said poxvirus and anti-PD-L1 antibody are performed.
Claims20
A method of for treating an HPV-positive cancer or HPV-positive precancerous intraepithelial lesions in a subject in need thereof, comprising administering to said subject a combination of:
- a) a poxvirus vector encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and an immunostimulatory cytokine, and
- b) an anti-PD-L1 antibody or antigen-binding fragment thereof,
- wherein a first administration of said poxvirus is performed 5 to 10 days before the first administration of said anti-PD-L1 antibody, and subsequent administrations of said poxvirus and anti-PD-L1 antibody are performed.
Dependencies are inferred from the claim text.